The DDAH-ADMA-NOS pathway

Leiper, J. M. (2005) The DDAH-ADMA-NOS pathway. Therapeutic Drug Monitoring, 27(6), pp. 744-746. (doi: 10.1097/01.ftd.0000179849.42395.11) (PMID:16404814)

Full text not currently available from Enlighten.


An increasing number of reports in the literature indicate that endogenously produced inhibitors of nitric oxide synthase (NOS),particularly asymmetric dimethylarginine (ADMA), regulate nitric oxide generation in disease states. This article describes the biology of ADMA and the implications for cardiovascular physiology and pathophysiology.

Item Type:Articles
Additional Information:Proceedings of the 9th International Congress of Therapeutic Drug Monitoring & Clinical Toxicology, Louisville, Kentucky, April 23-28, 2005
Glasgow Author(s) Enlighten ID:Leiper, Professor James
Authors: Leiper, J. M.
College/School:College of Medical Veterinary and Life Sciences > Institute of Cardiovascular and Medical Sciences
Journal Name:Therapeutic Drug Monitoring
Publisher:Lippincott, Williams & Wilkins
ISSN (Online):1536-3694

University Staff: Request a correction | Enlighten Editors: Update this record